Abstract
Alzheimer disease (AD) is a neurodegenerative disease that affects cognition, behavior and function. The etiology of the disease is unknown, however, the Primary Risk Factors for AD are aging, and family history. Neurofibrillary tangles (NFT) and amyloid-bearing neuritic plaques in the limbic and cerebral cortices are the characteristic neuropathologic lesions in brains of patients with AD. The NFT is mainly composed of hyprephosphorylated tau, whereas the major component of the neuritic plaques is the amyloid beta (Aβ) protein. The clinical diagnosis of probable AD is based on history, physical examination, neuropsychological testing, laboratory studies and neuroimaging techniques. However, there is no specific laboratory marker to support the diagnosis of definite AD or monitoring the progression of the disease. Several biochemical markers related to neuropathology have been identified in cerebrospinal fluid (CSF). We describe the studies of CSF or blood levels of amyloid β protein in patients with AD and age-matched nondemented controls. Due to the heterogeneity and complex nature of the disease, it is highly unlikely that that a single marker specific for AD will be found.
Keywords: Alzheimer disease, amyloid beta protein, cerebrospinal fluid, plasma
Current Alzheimer Research
Title: Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Volume: 4 Issue: 4
Author(s): Pankaj D. Mehta
Affiliation:
Keywords: Alzheimer disease, amyloid beta protein, cerebrospinal fluid, plasma
Abstract: Alzheimer disease (AD) is a neurodegenerative disease that affects cognition, behavior and function. The etiology of the disease is unknown, however, the Primary Risk Factors for AD are aging, and family history. Neurofibrillary tangles (NFT) and amyloid-bearing neuritic plaques in the limbic and cerebral cortices are the characteristic neuropathologic lesions in brains of patients with AD. The NFT is mainly composed of hyprephosphorylated tau, whereas the major component of the neuritic plaques is the amyloid beta (Aβ) protein. The clinical diagnosis of probable AD is based on history, physical examination, neuropsychological testing, laboratory studies and neuroimaging techniques. However, there is no specific laboratory marker to support the diagnosis of definite AD or monitoring the progression of the disease. Several biochemical markers related to neuropathology have been identified in cerebrospinal fluid (CSF). We describe the studies of CSF or blood levels of amyloid β protein in patients with AD and age-matched nondemented controls. Due to the heterogeneity and complex nature of the disease, it is highly unlikely that that a single marker specific for AD will be found.
Export Options
About this article
Cite this article as:
Mehta D. Pankaj, Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788891
DOI https://dx.doi.org/10.2174/156720507781788891 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Naturally Occurring and Synthetic Imidazoles: Their Chemistry and Their Biological Activities
Current Medicinal Chemistry Polymorphic Receptors of the Innate Immune System (MBL/MASP-2 and TLR2/4) and Susceptibility to Pneumococcal Bacteremia in HIV-Infected Patients: A Case-Control Study
Current HIV Research Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Characteristics of Behcet’s Disease in 453 Egyptian Patients Suffering from Uveitis with Gender Comparison
Current Rheumatology Reviews Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation A Review of Epidemic Models Related to Meteorological Factors
Current Bioinformatics Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews The Family of Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Infectious Disorders - Drug Targets Uveitis in Horses, Rats and Man: What Do We Learn from Our Pets?
Current Immunology Reviews (Discontinued) An Overview on Bacteriophages: A Natural Nanostructured Antibacterial Agent
Current Drug Delivery JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Neuroleptic Malignant Syndrome: A Pilot Study on Psychiatric Inpatients in Iran
Current Psychopharmacology Role of the Bacterial Type VI Secretion System in the Modulation of Mammalian Host Cell Immunity
Current Medicinal Chemistry Editorial [Is Drug Safety Dangerous?]
Current Drug Safety Small Molecule Hydrazide Agents to Inhibit Growth and Proliferation of Mycobacterium Tuberculosis
Medicinal Chemistry Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry